Science/AAAS | News
Fatal weakness. Pathogens such as methicillin-resistant Staphylococcus aureus (above) develop vulnerabilities as they evolve resistance to antibiotics. Choosing antibiotics that exploit these weaknesses can thwart resistant bacteria. Continue reading If Chosen Wisely, Existing Drugs Fight Resistant Bugs
US-based clinical stage drug discovery and development firm Celtaxsys has completed Phase I clinical trial of its drug CTX-4430 to treat patients with cystic fibrosis (CF) lung disease.
Celtaxsys Aus, the company’s Australian subsidiary, has carried out the first of two clinical trials in Continue reading Celtaxsys completes Phase I trial of cystic fibrosis drug
CARY, N.C., July 29, 2013 – Cornerstone Therapeutics Inc. (NASDAQ: CRTX) announced today it is now actively marketing PERTZYE® (pancrelipase) in the U.S. for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis. PERTZYE is the only U.S. Food and Drug Administration (FDA) approved pancreatic enzyme replacement therapy (PERT) containing Continue reading Cornerstone Therapeutics Initiates PERTZYE® (pancrelipase) Sales and Marketing Efforts for the Treatment of Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis
In an era of escalating resistance and lack of new antimicrobial discovery, stewardship programs must utilize knowledge of pharmacodynamics to achieve maximal exposure in the treatment of Pseudomonas aeruginosa infections. We evaluated the clinical and Continue reading Extended-Infusion Cefepime Reduces Mortality in Patients with Pseudomonas aeruginosa Infections; Bauer KA, West JE, O’Brien JM, Goff DA; Antimicrobial Agents & Chemotherapy (Apr 2013)
Pharmaxis Limited (ASX:PXS) has presented new analyses on the longer term benefits of its drug Bronchitol on cystic fibrosis sufferers.
The presentation at the European Cystic Fibrosis Society conference in Portugal, included the Continue reading Pharmaxis’ new drug progress in EU
It’s been nearly two and a half decades since the gene associated with the inherited disease cystic fibrosis was discovered, paving the way for disease-modifying drugs. In that time, only one such drug has been approved in the U.S. and Europe – Vertex’s Kalydeco. And that drug is only Continue reading For new Rhode Island firm, peptides hold hope for disease-altering cystic fibrosis treatments
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), and KaloBios Pharmaceuticals (KBIO) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Sanofi Pasteur for the investigation of KB001A, an Continue reading U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios’ Novel Biologic Candidate for Pseudomonas aeruginosa
N30 Pharmaceuticals, Inc., a clinical stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis (CF), announced today the presentation of key preclinical data for its novel inhibitors of S-nitrosoglutathione reductase (GSNORi). The data were Continue reading N30 Pharma Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
U.S. health regulators approved on Friday a hand-held inhaler made by Swiss drug maker Novartis AG to treat a type of bacterial lung infection that often affects cystic fibrosis patients.
Novartis’s TOBI Podhaler contains a dry powder formulation of tobramycin, an antibiotic used to Continue reading U.S. FDA OKs Novartis inhaler to treat lung infection in cystic fibrosis patients
Mar 19, 2013 – The US Food and Drug Administration (FDA) has completed its review of Pharmaxis’ New Drug Application (NDA) for its dry powder formulation of mannitol (Bronchitol, Pharmaxis) and has recommended that the company conduct an additional study to obtain Continue reading FDA Sends Cystic Fibrosis Treatment Back for More Study